Seeking Alpha

Amicus Therapeutics Inc. (FOLD)

()

Comments on FOLD

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm [View article]
    Chronic pain is very severe and this affects people's life, long known to people who suffered from a strange disease, were strong back... More »
    Comment by jameskildare
    Dec 7 11:22 am |
    Rating: 0 0
  • Developments for Parkinson's Disease Ignite Investor Enthusiasm [View article]
    A comprehensive review of the Parkinson's disease therapeutic landscape is beyond the scope of our article. Accordingly, we focused only... More »
    Comment by Michael Becker
    Nov 18 18:15 pm |
    Rating: 0 0
  • Developments for Parkinson's Disease Ignite Investor Enthusiasm [View article]
    Thank you. Unfortunately, we did not perform the currency translation - it was done by SA. On Nov 17 01:55 PM maxiedog wrote: >... More »
    Comment by Michael Becker
    Nov 18 15:39 pm |
    Rating: 0 0
  • Developments for Parkinson's Disease Ignite Investor Enthusiasm [View article]
    Mr. Becker! Why you don't mentioned Newron Pharma when you talk about drugs against PD? They have an adavanced product with good... More »
    Comment by Vitautas
    Nov 17 15:51 pm |
    Rating: +1 -1
  • Developments for Parkinson's Disease Ignite Investor Enthusiasm [View article]
    Check your UK pence to USD calculation. 10p is £0.1 not £1.
    Comment by maxiedog
    Nov 17 13:55 pm |
    Rating: 0 0
  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited [View article]
    Good job on the earnings call. It's a good thing your followers are not aware that you are a Habs fan as that would completely discredit... More »
    Comment by dasexiestman
    Oct 21 13:04 pm |
    Rating: 0 0
  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited [View article]
    One thing that always seems to be overlooked by everyone in the media is that Plicera and Genz-112638, in theory, have the possibility... More »
    Comment by OverloadedMama
    Oct 6 12:14 pm |
    Rating: 0 0
  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited [View article]
    Author correction: the Amicus press release was October 2, not October 5.
    Comment by Mark Mitchell
    Oct 6 09:44 am |
    Rating: 0 0
  • Trial setback is welcome news for Genzyme, but don't get too excited... [View instapost]
    Author error: the Amicus press release was dated October 2, not October 5.
    Comment by Mark Mitchell
    Oct 6 08:50 am |
    Rating: 0 0
  • Sell Genzyme Near Term Due to Continued Manufacturing Challenges [View article]
    Good Manufacturing Practice 101: Validate a contract manufacturer and sign a contract for back-up production of your drug. It's not... More »
    Comment by BioGuy
    Sep 24 21:01 pm |
    Rating: 0 0
  • Sell Genzyme Near Term Due to Continued Manufacturing Challenges [View article]
    There is a washout period (6 months) so unfortunately the impact to Amicus in the near term will be minimal. BTW, the trial is... More »
    Comment by ghmm
    Sep 24 08:56 am |
    Rating: 0 0
  • Shares of HGSI Up Big in Anticipation of Clinical Trials Update [View article]
    Thanks for HGSI
    Comment by aflitzy
    Aug 13 08:53 am |
    Rating: 0 0
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities [View article]
    The numerous recent lawsuits, positive data and prospects for accelerated approval of Shire's (SHPGY) competitive product, continued... More »
    Comment by Michael Becker
    Aug 5 16:06 pm |
    Rating: 0 0
  • Treating Parkinson’s Disease - Investment Opportunities and Challenges [View article]
    We are at the threshold of seeing marketable clinical applications for all the clinical pharmocogenomics research that has gone on for... More »
    Comment by Doc 224899
    Aug 3 12:28 pm |
    Rating: 0 0
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities [View article]
    Mike: I appreciate the article and agree with the comment above. At $53.83, GENZ looks like a good buy. Investors might consider... More »
    Comment by Justin M. Hall
    Jul 21 01:23 am |
    Rating: +1 -1